Skip to main content

Table 2 Evaluation of disease activity score or clinical symptoms in 16 patients

From: Efficacy and safety of thalidomide in children with monogenic autoinflammatory diseases: a single-center, real-world-evidence study

No

Diagnosis

3 months before

Baseline

3 months

6 months

9 months

12 months

1

AGSa

3

3

3

3

3

3

2

AGSa

1.26

3

3

3

3

3

3

AGSa

0.2

0.2

0

0

-

-

4

Blau syndromeb

0

0

0

0

0

0

5

Blau syndromeb

6

12

12

-

-

-

6

Blau syndromeb

0

0

0

0

0

0

7

Blau syndromeb

30

30

12

4

-

-

8

CINCAc

35

28

10

8

2

4

9

CINCAc

7

7

14

5

0

0

10

DADA2

Persistent fever, rash, oral ulcers and celialgia

Persistent fever, rash, oral ulcers and celialgia

Reduced fever frequency

Fever and celialgia improved

Few ulcers and rashes remained

Disappearance of rash

11

FMFc

15

15

0

0

0

0

12

HA20d

Mild

Mild

Disease-free activity

Disease-free activity

Disease-free activity

Disease-free activity

13

HA20d

Moderate

Moderate

Mild

Disease-free activity

Moderate

Disease-free activity

14

PLAID

Recurrent fevers and rash

Recurrent fevers and rash

Intermittent fever, rash and arthralgia

Intermittent fever, rash and arthralgia

Occasional fever and rash

Occasional fever and rash

15

SAVIe

3

3

1

2

2

-

16

TRAPSc

15

15

15

10

15

10

  1. aClinical score of AGS
  2. bNumber of active arthritis episodes
  3. cAIDAI
  4. dDisease severity of HA20
  5. eDisease activity rating scale of SAVI